Cimerli™ (ranibizumab-eqrn) from Coherus BioSciences has been approved as the first interchangeable biosimilar to Lucentis (ranibizumab injection). Cimerli is used to treat neovascular (wet) age-related macular degeneration (AMD)
- Cimerli is used to treat macular edema (swelling) caused by diabetes or by a blockage in the blood vessels. it is also used to treat diabetic retinopathy, the most common cause of vision loss in people with diabetes.
- Usual Adult Dose for Macular Degeneration:
- 5 mg via intravitreal injection once a month (approximately 28 days)
- Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. Patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.
- Use: Neovascular (wet) age-related macular degeneration (AMD)
- Usual Adult Dose for Macular Edema Following Retinal Vein Occlusion (RVO):
- 5 mg via intravitreal injection once a month (approximately 28 days)
- Use: Macular edema following retinal vein occlusion (RVO)
- Usual Adult Dose for Diabetic Macular Edema (DME):
- 3 mg via intravitreal injection once a month (approximately 28 days)
- Use: Diabetic macular edema (DME)
- Usual Adult Dose for Diabetic Retinopathy:
- 3 mg via intravitreal injection once a month (approximately 28 days)
- Use: Diabetic retinopathy
- Usual Adult Dose for Myopic Choroidal Neovascularization (mCNV):
- 5 mg via intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed
- Use: Myopic choroidal neovascularization (mCNV)
- No pricing information has been made available, but an October launch is anticipated.
